HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Chemoradionuclide therapy with 186Re-labeled liposomal doxorubicin in combination with radiofrequency ablation for effective treatment of head and neck cancer in a nude rat tumor xenograft model.

AbstractPURPOSE:
To determine the therapeutic efficacy of rhenium 186 ((186)Re)-labeled PEGylated liposomal doxorubicin ((186)Re-liposomal doxorubicin) in combination with radiofrequency (RF) ablation of human head and neck squamous cell carcinoma (HNSCC) xenograft in nude rats.
MATERIALS AND METHODS:
This investigation was approved by the animal care committee. Sixty nude rats with subcutaneously implanted HNSCC xenografts (six per group) were treated with (a) RF ablation (70 °C for 5 minutes), (b) PEGylated liposomes, (c) liposomal doxorubicin, (d) (186)Re-PEGylated liposomes (1295 MBq/kg), (e) (186)Re-liposomal doxorubicin (555 MBq/kg), (f) PEGylated liposomes plus RF ablation, (g) liposomal doxorubicin plus RF ablation, (h) (186)Re-PEGylated liposomes plus RF ablation, or (i) (186)Re-liposomal doxorubicin plus RF ablation. Six rats did not receive any treatment (control group). Tumor uptake in (186)Re therapy groups was monitored with small-animal single photon emission computed tomography for 5 days. Therapeutic efficacy was monitored for 6 weeks with measurement of tumor volume, calculation of the percentage injected dose of fluorine 18 fluorodeoxyglucose (FDG) in tumor from small-animal positron emission tomography (PET) images, and determination of viable tumor volume at histopathologic examination. Significant differences between groups were determined with analysis of variance.
RESULTS:
The average tumor volume (± standard deviation) on the day of therapy was 1.32 cm(3) ± 0.17. At 6 weeks after therapy, control of tumor growth was better with (186)Re-liposomal doxorubicin than with liposomal doxorubicin alone (tumor volume, 2.26 cm(3) ± 0.89 vs 5.43 cm(3) ± 0.93, respectively; P < .01). The use of RF ablation with liposomal doxorubicin and (186)Re-liposomal doxorubicin further improved tumor control (tumor volume, 2.05 cm(3) ± 1.36 and 1.49 cm(3) ± 1.47, respectively). The tumor growth trend correlated with change in percentage of injected dose of FDG in tumor for all groups (R(2) = 0.85, P < .001). Viable tumor volume was significantly decreased in the group treated with (186)Re-liposomal doxorubicin plus RF ablation (0.54 cm(3) ± 0.38; P < .001 vs all groups except (186)Re-liposomal doxorubicin alone).
CONCLUSION:
Triple and dual therapies had an observable trend ((186)Re-liposomal doxorubicin plus RF ablation > (186)Re-liposomal doxorubicin > liposomal doxorubicin plus RF ablation > liposomal doxorubicin) of improved tumor growth control and decreased viable tumor compared with other therapies. FDG PET could be used as a noninvasive surrogate marker for tumor growth and viability in this tumor model.
AuthorsAnuradha Soundararajan, Gerald D Dodd 3rd, Ande Bao, William T Phillips, Linda M McManus, Thomas J Prihoda, Beth A Goins
JournalRadiology (Radiology) Vol. 261 Issue 3 Pg. 813-23 (Dec 2011) ISSN: 1527-1315 [Electronic] United States
PMID22025735 (Publication Type: Journal Article)
Copyright© RSNA, 2011.
Chemical References
  • Antibiotics, Antineoplastic
  • Liposomes
  • Radiopharmaceuticals
  • Rhenium
  • Doxorubicin
Topics
  • Analysis of Variance
  • Animals
  • Antibiotics, Antineoplastic (administration & dosage, pharmacokinetics, pharmacology)
  • Carcinoma, Squamous Cell (diagnostic imaging, therapy)
  • Catheter Ablation
  • Chemotherapy, Adjuvant
  • Combined Modality Therapy
  • Disease Models, Animal
  • Doxorubicin (administration & dosage, pharmacokinetics, pharmacology)
  • Drug Synergism
  • Head and Neck Neoplasms (diagnostic imaging, therapy)
  • Isotope Labeling
  • Liposomes
  • Nuclear Medicine (methods)
  • Radionuclide Imaging
  • Radiopharmaceuticals (administration & dosage, pharmacokinetics, pharmacology)
  • Random Allocation
  • Rats
  • Rats, Nude
  • Rhenium (administration & dosage, pharmacokinetics, pharmacology)
  • Transplantation, Heterologous

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: